SCHEMBL13288889

SCHEMBL13288889

Bc1cnn2c(NCc3cccc(NC(=O)c4cccc(C(=O)OC)c4)c3)cc(-c3ccccc3Cl)nc12

nearest known ligand 0.47

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ GSK3B P49841 5/20 0.47
▸ CDK2 P24941 4/20 0.47
▸ RAB9A P51151 3/20 0.40
▸ NPC1 O15118 2/20 0.40
▸ SMN1; SMN2 Q16637 2/20 0.40
▸ HIF1A Q16665 1/20 0.40
▸ MEN1 O00255 1/20 0.40
▸ MAPT P10636 1/20 0.40
▸ KMT2A Q03164 1/20 0.40
▸ RET P07949 3/20 0.38
▸ KDR P35968 3/20 0.38
▸ POLB P06746 1/20 0.38
▸ PKM P14618 1/20 0.38
▸ ABL1 P00519 1/20 0.37
▸ TP53 P04637 1/20 0.37
▸ SENP5 Q96HI0 1/20 0.37
▸ SENP2 Q9HC62 1/20 0.37
▸ SENP1 Q9P0U3 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13119714 0.92 CDK2 (0.58) GSK3BCDK2RAB9ANPC1SMN1; SMN2
SCHEMBL13289130 0.89 RET (0.48) GSK3BCDK2MEN1MAPTKMT2A
SCHEMBL13288759 0.89 CDK2 (0.46) GSK3BCDK2SMN1; SMN2MEN1MAPT
SCHEMBL13288878 0.88 CDK2 (0.49) GSK3BCDK2RAB9ANPC1MEN1
SCHEMBL13288665 0.87 CDK2 (0.46) GSK3BCDK2MAPT
SCHEMBL13288642 0.87 CDK2 (0.49) GSK3BCDK2RETKDRSENP1
SCHEMBL13288729 0.86 CDK2 (0.51) GSK3BCDK2MEN1KMT2ASENP5
SCHEMBL13288880 0.86 CDK2 (0.44) GSK3BCDK2SMN1; SMN2MAPTRET
SCHEMBL13289111 0.85 CDK2 (0.52) GSK3BCDK2KDR
SCHEMBL13288663 0.85 CDK2 (0.47) GSK3BCDK2RAB9ANPC1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2194058-A1 Pyrazolopyrimidines suitable for the treatment of cancer diseases SCHERING CORPORATION (US) 2010-06-09 — — EP disclosed
Send feedback